Orforglipron has the clear lead in development, with completed Phase 3 trials, FDA filing, ATTAIN-MAINTAIN maintenance data, and the resources of Eli Lilly
Many Americans don't get all that they need from their diets either
Paracardiac adipose tissue is linked to worse heart outcomes, including increased inflammation and fibrosis
TransCon Technologies Overview Our TransCon technologies are designed to combine the benefits of conventional prodrug and sustained release technologies to solve the fundamental limitations seen in other approaches to extending duration of a drugs action in the body, with the goal of developing highly differentiated product candidates based on efficacy, safety, tolerability, and convenience
LC3-II, Microtubule Associated Protein 1 Light Chain 3-II (Lipidated Form)
Yang ZM, Wang Y, Chen SY